期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

克癃胶囊对大鼠前列腺增生及组织Ki-67、碱性成纤维细胞生长因子和血管内皮生长因子mRNA表达的影响 被引量：3

Effect of Kelong Capsule on Ki-67,bFGF and VEGF mRNA Expression in Benign Prostate Hyperplasia Tissues from Rats
原文传递
导出
摘要 目的探讨克癃胶囊对肾虚血瘀证大鼠前列腺增生的影响及其对前列腺增生相关蛋白、相关细胞因子的影响。方法建立前列腺增生肾虚血瘀证大鼠模型,观察空白对照组(A组),模型组(B组),非那雄胺组(C组),低、中、高剂量克癃给药组(D、E、F组)大鼠前列腺和前列腺相关因子的变化。结果①C～F组大鼠前列腺湿重、前列腺指数均显著低于B组(P<0.05)。②与B组比较,C、E、F组前列腺组织中Ki-67的积分光密度明显降低(P<0.01),D组无显著性差异(P>0.05)。③与B组比较,C、D、E、F组前列腺组织中碱性成纤维细胞生长因子的积分光密度明显降低(P<0.01);但D、E、F组前列腺组织中碱性成纤维细胞生长因子的积分光密度均高于C组(P<0.05)。④与B组比较,C、D、E、F组前列腺组织中血管内皮生长因子mRNA的表达降低(P<0.05);但D、E、F组前列腺组织中血管内皮生长因子mRNA的表达均较C组为高(P<0.05)。结论克癃胶囊可显著抑制大鼠前列腺增生,且呈剂量依赖性。可能与抑制前列腺增生相关蛋白及相关细胞因子的增高及表达密切相关,从而起到抑制前列腺增生的作用。 OBJECTIVE To study the effect of Kelong capsule on kidney deficiency and blood stasis rats prostatic hyperplasia and the prostatic hypeFplasia related protein and cell factors. METHODS Establish rat model for benign prostate hyperplasia with kidney deficiency and blood stasis syndrome and observe rats prostate and prostate correlation factors of blank control （ A）, model （B） , the fiuateride （C）, high, medium and low dose kelong （D, E, F）. RESULTS ①The prostate wet weight and prostate index of rats in groups C - F were significantly lower than that in group B （ P 〈 0. 05 ）. ②Compared with group B, Ki-67 integral optical density in prostate tissue obviously decreased in group C, E, F （P 〈 0. 01 ）, group D has no significant difference （P 〉 0. 05 ）. ③Compared with group B, bFGF integral optical density in prostate tissue in group C, D, E and F decreased obviously （P 〈 0. 01 ）but compared with group C, those in group D, E and F were significantly increased （P 〈 0. 05）. ④Compared with group B, VEGF mRNA expression in prostate tissue in group C, D, E and F were reduced （P 〈 0. 05） ; but those in group D, E and F were more than in C group （ P 〈 0. 05）. CONCLUSION Kelong capsule can dose-dependently inhibit prostatic hyperplasia in rats possibly through the inhibition of prostatic hyperplasia related protein and cell factors.
作者 颜苗 樊新荣 何清湖 龚慧
机构地区 中南大学湘雅二医院 中南大学临床药学研究所 湖南中医药大学
出处 《中国药学杂志》 CAS CSCD 北大核心 2013年第6期436-441,共6页 Chinese Pharmaceutical Journal
关键词 克癃胶囊 前列腺增生 肾虚血瘀证 前列腺增生相关细胞因子 Kelong capsule benign prostatic hyperplasia kidney deficiency and blood stasis syndrome prostatic hyperplasia related cell factor
分类号 R965 [医药卫生—药理学]
  • 相关文献

参考文献13

  • 1HE Q H. Discussion of the mechanism of benign prostate hyper-plasia kidney deficiency and blood stasis[ J]. 湖南中医学院学报,1997,17(2) :8-10.
  • 2ZHAO J Y,HE Q H. Kidney deficiency and blood stasis are thebasic pathogenesis of prostate hyperplasia [ J]. 新中医,2011,43(2):8-9.
  • 3樊新荣,孙涛,何清湖.克癃胶囊治疗良性前列腺增生的临床研究[J].医学综述,2010,16(16):2545-2547. 被引量：6
  • 4GERDES J,SCHWAB U,LEMKE H,et al. Produetion of mousemonoclonal antibody reactive with human nuclear antigen associat-ed with cell proliferation[ J]. Int J Cancer,1983 ,31(1) :13-16.
  • 5DENG F M. Proliferation and apoptosis ststes in benugn prostatichyperplasia[ J].中华外科杂志,1996,34( 10):620-622.
  • 6彭靖,张骞,虞巍,郭应禄,金杰.血管紧张素Ⅱ对大鼠增生前列腺细胞增殖和凋亡的影响[J].中华泌尿外科杂志,2006,27(9):615-617. 被引量：3
  • 7JIN J,NA Y Q. Pygeum of ricanum extract-tadenan in the treat-ment of benign prostatic hyperplasia[ J]. 中华泌尿外科杂志,1997,18(5) :293-295.
  • 8JIN L L, LI K, YANG Y F, et al. Research progress of benignprostatic hyperplasia drug targets [ J],中国药学杂志,2009, 44 (3) : 161-165.
  • 9TUTRONE R F,BALL R A,ORNITZ DM, et al Benign prostat-ic hyperplasia in a transgenic mouse : A new hormonally sensitiveinvestigatory mode] [ J]. J Urol,1993,149(3) ;633-639.
  • 10SHERWOOD E R, LEE C. Epidermal growth factor-related pep-tides and the epidermal growth receptor in normal and malignantprostate[J]. World J f/ro/, 1995 ,13 (5) :290-296.

二级参考文献27

  • 1张骞,彭靖,张祥华,郭应禄,金杰.环氧化酶-2对大鼠前列腺增生的影响及作用机理研究[J].中华泌尿外科杂志,2005,26(7):468-471. 被引量：7
  • 2张春和,陈天波,秦国政,丁世霖,李焱风.良性前列腺增生中医证型与尿动力学参数相关性研究[J].中华男科学杂志,2007,13(2):185-188. 被引量：17
  • 3Guess HA.Epidemiology and natural history of benign prostatic by perplasia[J].Urol Clin North Am,1995,22(2):247-261.
  • 4冷方南.中医男科诊疗学[M].北京:人民卫生出版社,1991:316-317.
  • 5Andriole GL,Kirby R.Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia[J].Eur Urol,2003,44(1):82-88.
  • 6Doll JA, Reiher FK, Crawford SE, et al. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor - 2 are key functional regulators of angiogenesis in the prostate[J]. Prostate, 2001; 49 (4): 293 - 305.
  • 7Barleon B, Sieister G, Martiny - Baron G, et al. Vascular endothdial growth factor up- regulates its receptor fims- like tyrosine linase(Flt - 1 ) and a soluble variant of Flt- 1 in human vascular endothelial cells[J]. Cancer Res, 1997;57(23) :5421 - 5425
  • 8Ravindranath N, Wion D, Bracher P, et al. Eidermal Growth factor modulated the expression of vascular endothelial growth factor in the human prostate[J]. JAndrol,2001 ;22(3):432 - 443.
  • 9Welder N, Folkman J, Pozza F, et al. Tumor angiogenesis;anew significant and independent prognostic indicator in early syage breast carcinoma[ J ]. JNatl Cancer Inst, 1992; 84: 1875 -1882.
  • 10Lin P,Sanlar S, Shan S, et al. Inhitition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor [J]. Cell grow Differ, 1998; 9:49.

共引文献11

同被引文献11

引证文献3

二级引证文献6

中国药学杂志
2013年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部